[HTML][HTML] Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and …

NA Johnson, GW Slack, KJ Savage… - Journal of clinical …, 2012 - ncbi.nlm.nih.gov
NA Johnson, GW Slack, KJ Savage, JM Connors, S Ben-Neriah, S Rogic, DW Scott, KL Tan…
Journal of clinical oncology, 2012ncbi.nlm.nih.gov
Purpose Diffuse large B-cell lymphoma (DLBCL) is curable in 60% of patients treated with
rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). MYC
translocations, with or without BCL2 translocations, have been associated with inferior
survival in DLBCL. We investigated whether expression of MYC protein, with or without
BCL2 protein expression, could risk-stratify patients at diagnosis.
Abstract
Purpose
Diffuse large B-cell lymphoma (DLBCL) is curable in 60% of patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). MYC translocations, with or without BCL2 translocations, have been associated with inferior survival in DLBCL. We investigated whether expression of MYC protein, with or without BCL2 protein expression, could risk-stratify patients at diagnosis.
ncbi.nlm.nih.gov